DOW JONES21,636.78-915.39 -4.06%
S&P 5002,541.47-88.60 -3.37%
NASDAQ7,502.38-295.16 -3.79%

UroGen Pharma Q4 EPS $(1.86) Misses $(1.70) Estimate

UroGen Pharma (NASDAQ:URGN) reported quarterly losses of $(1.86) per share which missed the analyst consensus estimate of $(1.7) by 9.41 percent. This is a 27.4 percent decrease over losses of $(1.46) per share from the

Benzinga · 03/02/2020 13:04

UroGen Pharma (NASDAQ:URGN) reported quarterly losses of $(1.86) per share which missed the analyst consensus estimate of $(1.7) by 9.41 percent. This is a 27.4 percent decrease over losses of $(1.46) per share from the same period last year.